Dosing Begins for GOG US Cervical Cancer Study Evaluating ADXS-HPV

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced at the OneMedForum in San Francisco that patient dosing has begun in the Gynecologic Oncology Group (GOG) 67 patient Phase 2 study evaluating Advaxis’ ADXS-HPV construct for the treatment of advanced cervical cancer. The study is sponsored by the GOG with the majority of funding from the National Cancer Institute.

The GOG study is in a patient population similar to the ongoing 110 patient study that Advaxis is conducting in India. Both studies will assess safety and efficacy in cervical cancer patients who have not responded to conventional cytotoxic treatment and whose cancer has metastasized and resumed growth. Details about the GOG-sponsored study can be found at Identifier NCT01266460.

“This study will complement our cervical cancer trial in India and, upon completion of enrollment for both trials, result in a total of over 170 patients in our Phase 2 cervical cancer program,” commented Advaxis Chairman & CEO Tom Moore. “Enrollment for the study in India is about 80% complete. We will release additional data on January 25 at the World Cancer Immunotherapy Congress in San Diego.”

About the Gynecologic Oncology Group (GOG)

The Gynecologic Oncology Group (GOG) is one of the National Cancer Institute's (NCI) funded cooperative cancer research groups. GOG is the only group that focuses its research on women with pelvic malignancies, such as cancer of the ovary, uterus, and cervix. It is a non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. The Group is committed to maintaining the highest standards in clinical trials development, execution, analysis, and distribution of results. Additional information can be found at: Protocol information for the GOG-sponsored study can be found at Identifier NCT01266460.

January is Cervical Health Awareness Month

The United States Congress designated January as Cervical Health Awareness Month to highlight issues related to cervical cancer, HPV disease, and the importance of early detection. This month is dedicated to bringing awareness to the personal stories of women and family members/caregivers battling issues related to their persistent HPV/pre-cancer and/or cervical cancer and to place an emphasis on the importance of early detection, education, and the emotional issues related to cervical cancer and HPV. For more information please visit:

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

Advaxis’ most advanced construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials for HPV-associated diseases: CIN 2/3 (US study, Clinical Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neck cancer (CRUK study) with over 150 patients receiving over 350 doses to date. Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, and others. For more information please visit: | Facebook | twitter | LinkedIn

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2010, which is available at The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.


Advaxis, Inc.
Diana Moore, 609-452-9814
Director, Investor Relations & Business Development
[email protected]

KEYWORDS:   United States  North America  California  New Jersey

INDUSTRY KEYWORDS:   Women  Health  Biotechnology  Clinical Trials  Infectious Diseases  Oncology  Consumer